B6-hANGPTL7 Mouse
Product Name
B6-hANGPTL7 Mouse
Product ID
C001789
Strain Name
C57BL/6JCya-Angptl7tm1(hANGPTL7)/Cya
Backgroud
C57BL/6JCya
Status
When using this mouse strain in a publication, please cite “B6-hANGPTL7 Mouse (Catalog C001789) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
ANGPTL7
Gene Alias
AngX, CDT6, dJ647M16.1
NCBI ID
Chromosome
Chr 1 (Human)
MGI ID
Datasheet
Strain Description
The ANGPTL7 gene encodes a secreted protein within the angiopoietin-like family, distinguished by its N-terminal coiled-coil domain and C-terminal fibrinogen-like domain. This protein is instrumental in extracellular matrix formation and organization, and functions as a negative regulator of angiogenesis, essential for maintaining corneal avascularity [1]. ANGPTL7 expression is highly prominent in the corneal stroma and ocular trabecular meshwork, the latter being critical for intraocular pressure (IOP) regulation. Its presence is also noted in adipose, neural, uterine, and hematopoietic stem/progenitor cells, where it influences lipid metabolism, inflammation, and hematopoiesis. Dysregulation of ANGPTL7 is significantly implicated in several pathologies, most notably glaucoma, type 2 diabetes mellitus (T2DM), and obstructive sleep apnea (OSA) [1-3]. In glaucoma, elevated ANGPTL7 in the trabecular meshwork enhances extracellular matrix deposition, increasing aqueous humor outflow resistance and consequently IOP [1]. For T2DM, ANGPTL7 contributes to insulin resistance through SOCS3 upregulation, leading to IRS1 degradation and compromised insulin signaling, thereby impairing glucose uptake [2]. In OSA, elevated ANGPTL7 levels correlate with disease severity, suggesting a role in the associated inflammatory, oxidative stress, and potential vascular remodeling processes [3].
The B6-hANGPTL7 mouse is a humanized model, constructed by replacing the sequences from 5'UTR to 3'UTR of the endogenous mouse Angptl7 gene with the corresponding human ANGPTL7 gene sequence. B6-hANGPTL7 mice can be used for research into the pathogenesis of glaucoma, type 2 diabetes mellitus (T2DM), and obstructive sleep apnea (OSA). They are also useful for the screening, development, and safety evaluation of ANGPTL7-targeted drugs.
Reference
Brown SF, Nguyen H, Mzyk P, De Ieso ML, Unser AM, Brown I, Ramesh P, Afzaal H, Ahmed F, Torrejon KY, Nhan A, Markrush D, Daly T, Knecht E, McConaughy W, Halmos S, Liu ZL, Rennard R, Peterson A, Stamer WD. ANGPTL7 and Its Role in IOP and Glaucoma. Invest Ophthalmol Vis Sci. 2024 Mar 5;65(3):22.
Xu T, Xu L, Meng P, Ma X, Yang X, Zhou Y, Feng M. Angptl7 promotes insulin resistance and type 2 diabetes mellitus by multiple mechanisms including SOCS3-mediated IRS1 degradation. FASEB J. 2020 Oct;34(10):13548-13560.
Leentjens M, Alterki A, Abu-Farha M, Bosschieter PFN, de Raaff C, de Vries C, Al Shawaf E, Thanaraj TA, Al-Khairi I, Cherian P, Channanath A, Kavalakatt S, van Wagensveld BA, de Vries N, Abubaker J. Increased plasma ANGPTL7 levels with increased obstructive sleep apnea severity. Front Endocrinol (Lausanne). 2022 Aug 9;13:922425.
Strain Strategy
The sequences from 5'UTR to 3'UTR of the endogenous mouse Angptl7 gene will be replaced with the sequences from 5'UTR to 3'UTR of the human ANGPTL7 gene.
Figure 1. Gene editing strategy of B6-hANGPTL7 Mice.
Application Area
ANGPTL7-targeted drug screening, development, and evaluation;
Research on the pathological mechanisms and therapeutic approaches of glaucoma;
Research on the pathological mechanisms and therapeutic approaches of type 2 diabetes mellitus (T2DM) and obstructive sleep apnea (OSA).
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
